Business Description
ACADIA Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0042251084
Share Class Description:
FRA:DR6: Ordinary SharesDescription
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.45 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.4 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.9 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.4 | |||||
| 3-Year EBITDA Growth Rate | 38.8 | |||||
| 3-Year EPS without NRI Growth Rate | 40.9 | |||||
| 3-Year FCF Growth Rate | 46.1 | |||||
| 3-Year Book Growth Rate | -12.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 16.22 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.36 | |||||
| 9-Day RSI | 53.53 | |||||
| 14-Day RSI | 54.82 | |||||
| 6-1 Month Momentum % | 10.75 | |||||
| 12-1 Month Momentum % | -36.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.29 | |||||
| Quick Ratio | 2.11 | |||||
| Cash Ratio | 1.64 | |||||
| Days Inventory | 235.21 | |||||
| Days Sales Outstanding | 38.31 | |||||
| Days Payable | 82.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1 | |||||
| Shareholder Yield % | -0.23 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.61 | |||||
| Operating Margin % | 12.08 | |||||
| Net Margin % | 13.83 | |||||
| FCF Margin % | 21.76 | |||||
| ROE % | 27.32 | |||||
| ROA % | 15.57 | |||||
| ROIC % | 51.02 | |||||
| 3-Year ROIIC % | 223.57 | |||||
| ROC (Joel Greenblatt) % | 203.67 | |||||
| ROCE % | 21.17 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.13 | |||||
| Forward PE Ratio | 23.44 | |||||
| PE Ratio without NRI | 22.13 | |||||
| Price-to-Owner-Earnings | 21.55 | |||||
| PEG Ratio | 0.99 | |||||
| PS Ratio | 3.08 | |||||
| PB Ratio | 4.97 | |||||
| Price-to-Tangible-Book | 6.07 | |||||
| Price-to-Free-Cash-Flow | 14.09 | |||||
| Price-to-Operating-Cash-Flow | 14.09 | |||||
| EV-to-EBIT | 20.99 | |||||
| EV-to-Forward-EBIT | 14.4 | |||||
| EV-to-EBITDA | 18.92 | |||||
| EV-to-Forward-EBITDA | 17.76 | |||||
| EV-to-Revenue | 2.54 | |||||
| EV-to-Forward-Revenue | 2.3 | |||||
| EV-to-FCF | 11.62 | |||||
| Price-to-Graham-Number | 2.45 | |||||
| Price-to-Net-Current-Asset-Value | 7.37 | |||||
| Price-to-Net-Cash | 17.29 | |||||
| Earnings Yield (Greenblatt) % | 4.76 | |||||
| FCF Yield % | 7.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ACADIA Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 851.625 | ||
| EPS (TTM) (€) | 0.715 | ||
| Beta | -0.3 | ||
| Volatility % | 41.7 | ||
| 14-Day RSI | 54.82 | ||
| 14-Day ATR (€) | 0.346429 | ||
| 20-Day SMA (€) | 16.586 | ||
| 12-1 Month Momentum % | -36.65 | ||
| 52-Week Range (€) | 13.055 - 27.2 | ||
| Shares Outstanding (Mil) | 166.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ACADIA Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ACADIA Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
ACADIA Pharmaceuticals Inc Frequently Asked Questions
What is ACADIA Pharmaceuticals Inc(FRA:DR6)'s stock price today?
The current price of FRA:DR6 is €16.95. The 52 week high of FRA:DR6 is €27.20 and 52 week low is €13.06.
When is next earnings date of ACADIA Pharmaceuticals Inc(FRA:DR6)?
The next earnings date of ACADIA Pharmaceuticals Inc(FRA:DR6) is 2025-02-27 Est..
Does ACADIA Pharmaceuticals Inc(FRA:DR6) pay dividends? If so, how much?
ACADIA Pharmaceuticals Inc(FRA:DR6) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers